BCYC - Bicycle Therapeutics Ltd Stock Price, Fair Value and News

$20.52-0.06 (-0.29%)

Delayed as of 25 Nov 2024, 01:36 pm ET

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

BCYC Price Action

Last 7 days

-5.5%

Last 30 days

-18.7%

Last 90 days

-8.0%

Trailing 12 Months

48.9%

BCYC RSI Chart

BCYC Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-8.54

Price/Sales (Trailing)

38.49

EV/EBITDA

-3.36

Price/Free Cashflow

-6.98

BCYC Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

BCYC Fundamentals

BCYC Revenue

Revenue (TTM)

36.9M

Rev. Growth (Yr)

-50%

Rev. Growth (Qtr)

-71.41%

BCYC Earnings

Earnings (TTM)

-166.3M

Earnings Growth (Yr)

-1.81%

Earnings Growth (Qtr)

-27.6%

BCYC Profitability

EBT Margin

-459.75%

Return on Equity

-20.01%

Return on Assets

-16.68%

Free Cashflow Yield

-14.33%

BCYC Investor Care

Shares Dilution (1Y)

74.39%

Diluted EPS (TTM)

-3.25

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	41.6M	39.6M	36.9M	0
2023	15.5M	22.5M	24.8M	27.0M
2022	13.7M	16.3M	15.0M	14.5M
2021	11.1M	11.3M	11.8M	11.7M
2020	8.5M	8.6M	11.8M	10.4M
2019	10.7M	10.6M	9.6M	13.8M
2018	3.3M	4.6M	5.9M	7.1M
2017	0	0	0	2.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Bicycle Therapeutics Ltd

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528, a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149, a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA; and BT7401, a multivalent CD137 agonist. In addition, it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, dementia, central nervous system, neuromuscular, and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB, Sanofi, Oxurion NV, and the Dementia Discovery Fund, as well as with Ionis Pharmaceuticals, Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets, as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

WEBSITE	bicycletherapeutics.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	236

Bicycle Therapeutics Ltd Frequently Asked Questions

What is the ticker symbol for Bicycle Therapeutics Ltd? What does BCYC stand for in stocks?

BCYC is the stock ticker symbol of Bicycle Therapeutics Ltd. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Bicycle Therapeutics Ltd (BCYC)?

As of Fri Nov 22 2024, market cap of Bicycle Therapeutics Ltd is 1.42 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BCYC stock?

You can check BCYC's fair value in chart for subscribers.

Is Bicycle Therapeutics Ltd a good stock to buy?

The fair value guage provides a quick view whether BCYC is over valued or under valued. Whether Bicycle Therapeutics Ltd is cheap or expensive depends on the assumptions which impact Bicycle Therapeutics Ltd's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BCYC.

What is Bicycle Therapeutics Ltd's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Nov 22 2024, BCYC's PE ratio (Price to Earnings) is -8.54 and Price to Sales (PS) ratio is 38.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BCYC PE ratio will change depending on the future growth rate expectations of investors.